Cargando…
Review of daclizumab and its therapeutic potential in the treatment of relapsing–remitting multiple sclerosis
Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system. It can present in several forms, with the relapsing–remitting pattern being the most common. Since the approval of the first disease-modifying therapy and the initiation of appropriate treatments f...
Autores principales: | Reardon, Jennifer, Perumal, Jai S |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3797609/ https://www.ncbi.nlm.nih.gov/pubmed/24143075 http://dx.doi.org/10.2147/DDDT.S27766 |
Ejemplares similares
-
Effect of daclizumab high-yield process in patients with highly active relapsing-remitting multiple sclerosis
por: Giovannoni, Gavin, et al.
Publicado: (2013) -
Spotlight on daclizumab: its potential in the treatment of multiple sclerosis
por: Milo, Ron, et al.
Publicado: (2016) -
Therapeutic efficacy of monthly subcutaneous injection of daclizumab in relapsing multiple sclerosis
por: Cohan, Stanley
Publicado: (2016) -
Pharmacokinetics of daclizumab high-yield process with repeated administration of the clinical subcutaneous regimen in patients with relapsing-remitting multiple sclerosis
por: Tran, Jonathan Q, et al.
Publicado: (2016) -
Improved cognitive outcomes in patients with relapsing–remitting multiple sclerosis treated with daclizumab beta: Results from the DECIDE study
por: Benedict, Ralph HB, et al.
Publicado: (2017)